Sugi Predict

Sugi Predict / Targets / GSK3B

GSK3B

Glycogen synthase kinase-3 beta · P49841 · GSK3B on Sugi Atlas →

507,978 patent compounds predicted against GSK3B, 290,726 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Sparfloxacin Sparfloxacin (SCHEMBL41311) 0.60 12/20
SCHEMBL7621 SCHEMBL7621 1.00 11/20
Bromide Bromide (SCHEMBL66813) 0.58 9/20
SCHEMBL44251 SCHEMBL44251 0.48 9/20
Thiazesim Thiazesim (SCHEMBL49862) 0.65 8/20
SCHEMBL19938 SCHEMBL19938 0.54 8/20
SCHEMBL26286 SCHEMBL26286 0.50 8/20
Daph Daph (SCHEMBL11017) 0.52 6/20
SCHEMBL61934 SCHEMBL61934 0.39 6/20
SCHEMBL1356 SCHEMBL1356 0.38 6/20
Sb-216763 Sb-216763 (SCHEMBL30251) 1.00 5/20
SCHEMBL38645 SCHEMBL38645 1.00 5/20
SCHEMBL31318 SCHEMBL31318 0.50 5/20
SCHEMBL19982 SCHEMBL19982 0.44 5/20
SCHEMBL44956 SCHEMBL44956 0.42 5/20
SCHEMBL14757 SCHEMBL14757 0.80 4/20
SCHEMBL10658 SCHEMBL10658 0.65 4/20
SCHEMBL66923 SCHEMBL66923 0.60 4/20
SCHEMBL58313 SCHEMBL58313 0.59 4/20
SCHEMBL58543 SCHEMBL58543 0.57 4/20

Clinical trials — most relevant to GSK3B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Lithium for Prevention of Cognitive Declining in Mood Illnesses PHASE4NOT_YET_RECRUITING
Lithium As a Treatment to Prevent Impairment of Cognition in Elders PHASE4COMPLETED
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy PHASE2RECRUITING
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy PHASE2COMPLETED
Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis PHASE2COMPLETED
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria PHASE2NOT_YET_RECRUITING
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma PHASE2WITHDRAWN
A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB) PHASE2COMPLETED
A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults PHASE2COMPLETED
A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer PHASE2COMPLETED
A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis PHASE2COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA) PHASE1COMPLETED
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants PHASE1COMPLETED
GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers PHASE1COMPLETED
Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects PHASE1COMPLETED
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers PHASE1COMPLETED
Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma PHASE1COMPLETED
Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects PHASE1COMPLETED
First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect PHASE1COMPLETED
First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects PHASE1COMPLETED
GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1) PHASE1COMPLETED
GSK372475 PK Study in Healthy Volunteers PHASE1COMPLETED
A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male Subjects PHASE1COMPLETED
First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects PHASE1COMPLETED
Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002 PHASE1COMPLETED
A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults PHASE1COMPLETED
A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants PHASE1COMPLETED
Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects PHASE1COMPLETED
Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GSK3B binder may also engage these)

ProteinNameSimilarity
P18266 — 1.000 P18266 →
Q9WV60 — 1.000 Q9WV60 →
Q5YJC2 — 1.000 Q5YJC2 →
P51138 — 1.000 P51138 →
Q91757 — 1.000 Q91757 →
Q8VZD5 — 1.000 Q8VZD5 →
Q3S406 — 1.000 Q3S406 →
G4NH08 — 1.000 G4NH08 →
P43288 — 1.000 P43288 →
P43289 — 1.000 P43289 →
Q39010 — 1.000 Q39010 →
O04160 — 0.999 O04160 →
Q60EZ2 — 0.999 Q60EZ2 →
Q9U2Q9 — 0.999 Q9U2Q9 →
Q2NL51 — 0.999 Q2NL51 →
Q40518 — 0.998 Q40518 →
Q39012 — 0.998 Q39012 →
Q9LWN0 — 0.997 Q9LWN0 →
Q39011 — 0.996 Q39011 →
O23145 — 0.996 O23145 →
GSK3A Glycogen synthase kinase-3 alpha 0.995 landscape →
Q96287 — 0.995 Q96287 →
Q501Q9 — 0.995 Q501Q9 →
Q39019 — 0.994 Q39019 →
Q10452 — 0.994 Q10452 →
Q9FVS6 — 0.994 Q9FVS6 →
Q5SN53 — 0.994 Q5SN53 →
A8X5H5 — 0.994 A8X5H5 →
P18431 — 0.994 P18431 →
G5EBT1 — 0.994 G5EBT1 →